

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	ADHD, Methylphenidate Short Acting PDL Edit
<b>First Implementation Date:</b>	January 10, 2019
<b>Proposed Date:</b>	October 17, 2023
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Attention deficit hyperactivity disorder (ADHD) is a neuropsychiatric disorder with symptoms that affect cognitive, academic, occupational, behavioral, emotional, and social functioning. Although typically thought of as a childhood disease, many patients will require treatment into adulthood. Treatment recommendations for patients with ADHD vary based on age and include behavioral changes, cognitive therapy, and pharmacotherapy. Pharmacotherapy options include stimulants, such as methylphenidate and amphetamine, and nonstimulant medications.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Dexmethylphenidate</li> <li>Methylphenidate Soln/Tabs</li> </ul>	<ul style="list-style-type: none"> <li>Focalin®</li> <li>Methylphenidate Chew</li> <li>Methylin®</li> <li>Ritalin®</li> </ul>

**Type of Criteria:** ☐ Increased risk of ADE  
☒ Appropriate Indications

☒ Preferred Drug List  
☐ Clinical Edit

**Data Sources:** ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: ADHD: Methylphenidate, Short Acting
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Dosage within approved dosage limitations **AND**
- Participant demonstrates compliance to prescribed therapy **OR**
- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents

- Documented trial period for preferred agents (90 out of 120 days) **OR**
- Documented ADE/ADR to preferred agents
- Therapy may be approved for indications below (clinical consultant review may be required):
  - Attention deficit hyperactivity disorder
  - Idiopathic hypersomnia
  - In the treatment of cancer: depression or opioid-induced sedation
  - Narcolepsy
  - Stroke: as short-term adjunct for rehabilitation therapy
- Participant aged < 6 years:
  - Compliance authorization piece is removed (requires a yearly evaluation at minimum)
  - Confirmed diagnosis of ADHD with signs/symptoms in 2 or more settings using a standardized rating scale:
    - Conners' Rating Scale-Revised
    - [Vanderbilt ADHD Diagnostic Teacher Rating Scale-Bright Futures](#)
    - [Vanderbilt ADHD Diagnostic Teacher Rating Scale-UOHSC](#)
    - [Vanderbilt ADHD Diagnostic Parent Rating Scale](#)
    - [ADHD-RS](#)
    - [Additional Resources](#)

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results: ☐  
MedWatch Form: ☐

Progress Notes: ☒  
Other: ☒

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

3 months

## References

- Evidence-Based Medicine Analysis: "Attention Deficit Hyperactivity Disorder (ADHD)", UMKC-DIC; June 2023.
- Evidence-Based Medicine and Fiscal Analysis: "Attention Deficit Hyperactivity Disorder (ADHD) Agents – Therapeutic Class Review"-, Conduent Business Services, L.L.C., Richmond, VA; July 2021.
- Psychology Prior Authorization Advisory Committee Meeting. "Evidence-Based Practice Discussion – ADHD and Stimulant Therapy". MO HealthNet Division. November 2007.
- Drug Prior Authorization Sub-Committee Meeting. "ADHD Adult Therapy." Department of Mental Health/Division of Medical Services. March/April/June 2005.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.), Washington, DC; 2013.Lippincott, Williams, Wilkins.

*SmartPA PDL Proposal Form*

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.  
Other company trademarks are also acknowledged.

- Drug Effectiveness Review Project – Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. Center for Evidence-Based Policy, Oregon Health & Science University; September 2005/Updated July 2015; Preliminary Scan Report June 2016.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.

DRAFT